DnB Markets - YIT Oyj (YIT) YIT (Sell, TP: EUR2.00) - Finnish recovery not started yet

Report

DnB Markets

Simen Mortensen

EUR 477.89 For Business Accounts Only

YIT (Sell, TP: EUR2.00) - Finnish recovery not started yet

According to YIT, the Baltic and CEE residential markets have recovered – but Finland has still to see any sign of a rebound. Reported Q3 EBIT was broadly in line with our estimate, including a EUR6m one-off. The order backlog was down 18% YOY, another concern for us, but we believe it should improve in Q4. However, we continue to see downside risk to consensus, expecting the recovery to be slower than is reflected in the former and the share price. We reiterate our SELL and EUR2 target price.

01/11/2024 1 EN

Underlying

YIT Oyj

YIT provides services for the construction sector. Co. has two segments: Housing and Business Premises and Infrastructure. The Housing segment is engaged in the development and construction of housing, holiday homes and entire residential areas, with a focus on its own developments. This segment is also engaged in property maintenance in Russia. The Business Premises and Infrastructure segment is engaged in the development and construction of offices, shopping malls, public facilities, assisted living facilities and other business premises; renovation projects; construction of roads, bridges, tunnels, rail and metro stations, ports and power plants; as well as road and street maintenance.

See profile

FI0009800643 Nasdaq Nordic Helsinki Finland

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

Simen Mortensen

Other Reports on these Companies

DnB Markets

YIT (Sell, TP: EUR2.00) - New ambitions, but with a condition

At its CMD, the company presented new financial and non-financial targets through 2029. However, these depend on a reversion in the Finnish residential market to an historical average of c16,000 new housing starts annually. Given YIT’s track record of not achieving its financial targets, we have made no forecast changes. We reiterate our SELL and EUR2 target price, finding a better risk/reward elsewhere.

Free Trial

November 14, 2024 November 14, 2024 1 EN

DnB Markets

KPIs and profits reflect cycle-lows

While the sector has rallied on expectations of a recovery in Nordic CRE and residential starts, there are no signs of an actual recovery yet. With our base case still for a gradual sales recovery in 2026, our longer-term estimates remain below consensus, reflecting slow profit-recognition under IFRS – the latter also underlies our expectation of declining revenues and EBIT YOY in Q3 for several names we cover. Our sector top picks are still Skanska, NCC and Veidekke, while we see downside risk for AF Gruppen and the residential developers (YIT, JM, Peab and Selvaag Bolig). We maintain a neutr...

Free Trial

October 6, 2024 October 6, 2024 1 EN

Electrolux Professional (Hold, TP: SEK75.00) - Q4 looks set to be a repeat of Q3

We expect broadly similar market and divisional dynamics QOQ in Q4, but are less optimistic on growth in the US Food & Beverage segment (we now see the recovery materialising slightly later than initially envisaged). We forecast 6.0% growth YOY in group sales in Q4 and an adj. EBITA margin of 12.3%. We reiterate our HOLD, but have lowered our target price to SEK75 (79) based on our view of a delayed US Food & Beverage recovery as well as continued headwinds in the Middle East into 2025.

Free Trial

9h / 37m 9h / 37m 1 EN

Ebba Bjorklid

Ebba Bjorklid

Electrolux (Hold, TP: SEK92.00) - Uncertainty remains high

In Q4, we forecast similar demand and market dynamics to Q3, with consumer downtrading, elevated promotional activity, a negative mix, price pressure, and weak consumer demand weighing on sales and EBIT. We expect a sales decline of 1.6% YOY (organic growth of 2.6%) and an adj. EBIT margin of 3.2%. We reiterate our HOLD, but have cut our target price to SEK92 (94).

Free Trial

10h / 36m 10h / 36m 1 EN

Rune Majlund Dahl

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

In REDEFINE-1, CagriSema reached a 22.7% product estimand weight loss, shy of expectations. We expect a launch in 2026, but have lowered our estimate of its sales potential. In our view, the flexible protocol affected efficacy, prompting Novo Nordisk to initiate a new phase III trial in 2025. We reiterate our BUY, but have cut our target price to DKK1,040 (1,150).

Free Trial

December 20, 2024 December 20, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

YIT (Sell, TP: EUR2.00) - Finnish recovery not started yet

YIT (Sell, TP: EUR2.00) - New ambitions, but with a condition

KPIs and profits reflect cycle-lows

Electrolux Professional (Hold, TP: SEK75.00) - Q4 looks set to be a repeat of Q3

Electrolux (Hold, TP: SEK92.00) - Uncertainty remains high

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe